Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Feb 2017

Gong Jun, Wang Chongkai, Lee Peter P, Chu Peiguo, Fakih Marwan

Abstract excerpt

Recent clinical evidence has demonstrated that microsatellite instability (MSI) or defective mismatch repair (MMR) and high tumor mutational load can predict response to the programmed cell death 1 (PD-1) receptor inhibitor pembrolizumab in metastatic colorectal cancer (mCRC). Mutations in polymerase ε (POLE), a DNA polymerase involved in DNA replication and repair, contribute to an ultramutated but...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoembryonic Antigen

Share to Colonoscopy

Share to DNA Polymerase II

Share to Lymphocytes, Tumor-Infiltrating

Share to Poly-ADP-Ribose Binding Proteins

Share to Programmed Cell Death 1 Receptor

Source

Identifiers

PMID: 28188185
DOI: 10.6004/jnccn.2017.0016

Genes

POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation.PMID 28188185Read ↗

PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation.Semantic proximity Read ↗

Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumorsSemantic proximity Read ↗

Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε ( POLE )Semantic proximity Read ↗

Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.Semantic proximity Read ↗

POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval.Semantic proximity Read ↗

Four-Year Disease-Free Remission in a Patient With POLE Mutation-Associated Colorectal Cancer Treated Using Anti-PD-1 Therapy.Semantic proximity Read ↗

The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?Semantic proximity Read ↗

Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal CancerSemantic proximity Read ↗

Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant POLE/POLD1 Colon Cancer.Semantic proximity Read ↗

Polymerase Epsilon-Associated Ultramutagenesis in CancerSemantic proximity Read ↗

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.Semantic proximity Read ↗

Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.